Loading clinical trials...
Loading clinical trials...
Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)
Conditions
Interventions
Anti-CD19/CD20/CD22 CAR T-Cells
Cyclophosphamide
+7 more
Locations
2
United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Start Date
June 30, 2022
Primary Completion Date
April 30, 2026
Completion Date
July 31, 2026
Last Updated
May 16, 2025
NCT03128034
NCT03147612
NCT03808610
NCT02146924
NCT02879695
NCT02220985
The Ohio State University Comprehensive Cancer Center
CONTACT
800-293-5066OSUCCCClinicaltrials@osumc.eduLead Sponsor
Sumithira Vasu
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions